Franchini Indrani Lall
Known title: EVP, CLO & SecretaryCIK: 0001708764
Associated companies
Transaction History
| ALNY | ▼ Sell | Open Market | 142 | $22K | 2/28/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 111 | $17K | 2/28/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 66 | $10K | 2/28/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 1 | $158 | 2/28/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 9 | $1K | 2/28/2024 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 878 | $0 | 2/27/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 502 | $85K | 2/2/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 820 | $140K | 2/2/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 269 | $46K | 2/2/2024 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 5,175 | $0 | 2/1/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 3,500 | $735K | 4/6/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 77 | $17K | 2/2/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,007 | $227K | 2/2/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 586 | $133K | 2/2/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 5 | $1K | 2/2/2023 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 5,175 | $0 | 2/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets
Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.